Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered question first ministerially corrected answering member label attachment file name title previous answer version answering member printed answering member label
tabling member	label

Search

385291

	registered interest
	date	24/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Skin Cancer
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what guidelines are issued to Clinical Commissioning Groups regarding patients with high-risk skin cancers such as melanoma.
	tabling member printed	Lord Clark of Windermere
	uin	HL774
	answer	answer is ministerial correction date of answer 08/07/2015 answer text <p>NHS England has published a service specification for adult skin cancer services that sets out what the National Health Service must have in place to offer high quality skin cancer treatment, care and support. Embedded in this is the current best practice guidance on skin cancer published by the National Institute for Health and Care Excellence (NICE).</p><p> </p><p> </p><p> </p><p>NICE is developing a guideline on the assessment and management of melanoma. NICE currently expects to publish its final guidance in July 2015. Further information is available at the following link and a copy of the webpage has been attached.</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/guidance/indevelopment/gid-cgwave0674" target="_blank">www.nice.org.uk/guidance/indevelopment/gid-cgwave0674</a></p><p> </p><p> </p><p> </p><p>In addition, NICE is currently in the process of updating its Public Health guidance on skin cancer prevention: information, resources and environmental changes (PH32).</p><p> </p> answering member printed Lord Prior of Brampton question first answered 08/07/2015 13:52:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NICE webpage.pdf title NICE webpage
	tabling member	525 label Biography information for Lord Clark of Windermere

385293

	registered interest
	date	24/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is the total value of projected savings to be made by removing drugs and indications from the Cancer Drugs Fund in England over (1) Q1 of 2015–16, and (2) the whole of 2015–16.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL776
	answer	answer is ministerial correction date of answer 02/07/2015 answer text <p> </p><p /> <p>NHS England has advised that the projected value of savings from the Cancer Drugs Fund, as a result of removing drugs from the national list, is not yet available.</p><p /> <p> </p><p /> <p> </p><p /> <p> </p><p /> <p>Decisions to de-list drugs were made taking account of the need to ensure the limited resources of the Fund are used most effectively. Advances in medical science mean that new and exciting cancer medicines are emerging all the time and we want people to have access to these too.</p><p /> <p> </p><p /> <p> </p><p /> <p> </p><p /> <p>The Government established the Cancer Drugs Fund to ensure that cancer patients in England have better access to life-extending and improving drugs not routinely funded by the National Health Service.</p><p /> <p> </p><p /> <p> </p><p /> <p> </p><p /> <p>Between October 2010 and March 2015, the Fund has helped over 72,000 cancer patients.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 02/07/2015 15:54:13 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

385294

	registered interest
	date	24/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cancer Drugs Fund
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the impact of delisting from the Cancer Drugs Fund on the availability of cancer drugs in the United Kingdom, in comparison with (1) the level of access in 2010 when the Fund was introduced, and (2) availability levels in comparable European countries.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL777
	answer	answer is ministerial correction date of answer 02/07/2015 answer text <p>Neither the Department nor NHS England has made any such assessment.</p><p> </p><p> </p><p> </p><p>Decisions to de-list drugs were made taking account of the need to ensure the limited resources of the Fund are used most effectively. Advances in medical science mean that new and exciting cancer medicines are emerging all the time and we want people to have access to these too.</p><p> </p><p> </p><p> </p><p>The Government established the Cancer Drugs Fund to ensure that cancer patients in England have better access to life-extending and improving drugs not routinely funded by the NHS.</p><p> </p><p> </p><p> </p><p>Between October 2010 and March 2015, the Fund has helped over 72,000 cancer patients.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 02/07/2015 15:55:02 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

385295

	registered interest
	date	24/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Clinical Commissioning Groups
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what action they plan to take in the event of the Clinical Commissioning Groups outsourcing parts of their commissioning role to get round the restrictions on administrative costs.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL778
	answer	answer is ministerial correction date of answer 29/06/2015 answer text <p>Clinical commissioning groups (CCGs), as independent statutory bodies, can choose how best to carry out their commissioning functions from within their running cost budget.</p><p> </p><p> </p><p> </p><p>Where CCGs choose to outsource their support and to buy from external providers, this funding will be charged against their fixed running cost allowance.</p><p> </p><p> </p><p> </p><p>Service integrators and lead providers co-ordinate and provide care for patients; they are not commissioners, nor do they undertake commissioning activities or responsibilities.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL779 HL780 question first answered 29/06/2015 15:05:34 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

385296

	registered interest
	date	24/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Clinical Commissioning Groups
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, when Clinical Commissioning Groups outsource some of their commissioning role to integrators, lead providers or through other similar mechanisms, how the administrative costs so transferred will be counted against the Clinical Commissioning Groups' administrative cost cap.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL779
	answer	answer is ministerial correction date of answer 29/06/2015 answer text <p>Clinical commissioning groups (CCGs), as independent statutory bodies, can choose how best to carry out their commissioning functions from within their running cost budget.</p><p> </p><p> </p><p> </p><p>Where CCGs choose to outsource their support and to buy from external providers, this funding will be charged against their fixed running cost allowance.</p><p> </p><p> </p><p> </p><p>Service integrators and lead providers co-ordinate and provide care for patients; they are not commissioners, nor do they undertake commissioning activities or responsibilities.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL778 HL780 question first answered 29/06/2015 15:05:33 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

385297

	registered interest
	date	24/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Clinical Commissioning Groups
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether, when Clinical Commissioning Groups outsource some of their commissioning role, the element of administration that would have counted towards the fixed cap on administrative costs will be separately identified and appropriately deducted from Clinical Commissioning Group budgets.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL780
	answer	answer is ministerial correction date of answer 29/06/2015 answer text <p>Clinical commissioning groups (CCGs), as independent statutory bodies, can choose how best to carry out their commissioning functions from within their running cost budget.</p><p> </p><p> </p><p> </p><p>Where CCGs choose to outsource their support and to buy from external providers, this funding will be charged against their fixed running cost allowance.</p><p> </p><p> </p><p> </p><p>Service integrators and lead providers co-ordinate and provide care for patients; they are not commissioners, nor do they undertake commissioning activities or responsibilities.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL778 HL779 question first answered 29/06/2015 15:05:34 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

385300

	registered interest
	date	24/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Liver Diseases
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether the programme of work for liver disease being developed by Public Health England will include a hepatitis C improvement framework.
	tabling member printed	Baroness Masham of Ilton
	uin	HL783
	answer	answer is ministerial correction date of answer 08/07/2015 answer text <p>NHS England and Public Health England (PHE) are working alongside a coalition of other organisations and patient groups to draft a framework for hepatitis C improvement. This hepatitis C improvement framework will set high level aims for the public health system towards elimination of hepatitis C related liver disease as a significant public health concern.</p><p> </p><p> </p><p> </p><p>The hepatitis C improvement framework will be referred to in PHE’s liver disease framework.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 08/07/2015 14:54:40 answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	1850 label Biography information for Baroness Masham of Ilton

385301

	registered interest
	date	24/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Hepatitis
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government why the national waiting time criterion for referral to hepatitis C treatment is 18 weeks whereas the national waiting time criterion for referral to specialist services for HIV treatment is two weeks.
	tabling member printed	Baroness Masham of Ilton
	uin	HL784
	answer	answer is ministerial correction date of answer 08/07/2015 answer text <p><del class="ministerial">NHS England and Public Health England (PHE) are working alongside a coalition of other organisations and patient groups to draft a framework for hepatitis C improvement. This hepatitis C improvement framework will set high level aims for the public health system towards elimination of hepatitis C related liver disease as a significant public health concern.</del></p><p> </p><p> </p><p> </p><p><del class="ministerial">The hepatitis C improvement framework will be referred to in PHE’s liver disease framework.</del></p><p> </p><p><ins class="ministerial">Timing for access to care or treatments for all NHS England service specifications or policies is based on an assessment of the evidence for clinical effectiveness, cost effectiveness and affordability.</ins></p><p> </p><p> </p> answering member printed Lord Prior of Brampton question first answered 08/07/2015 13:53:15 question first ministerially corrected 08/07/2015 14:59:37 answering member 127 label Biography information for Lord Prior of Brampton previous answer version 12907 answering member printed Lord Prior of Brampton answering member 127 label Biography information for Lord Prior of Brampton
	tabling member	1850 label Biography information for Baroness Masham of Ilton

385304

	registered interest
	date	24/06/2015
	answering body	Department for Business, Innovation and Skills
	answering dept id	26
	answering dept short name	Business, Innovation and Skills
	answering dept sort name	Business, Innovation and Skills
	hansard heading	Cole Commission on Exports
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what assessment they have made of the report by the Cole Commission on Exports <i>An Action Plan from business</i>.
	tabling member printed	Lord Harrison
	uin	HL787
	answer	answer is ministerial correction date of answer 29/06/2015 answer text <p>The Government welcomes this report and the serious work by members of the Cole Commission. It contains much invaluable analysis and we will consider its recommendations very carefully.</p><p> </p> answering member printed Lord Maude of Horsham question first answered 29/06/2015 12:23:26 answering member 115 label Biography information for Lord Maude of Horsham
	tabling member	2488 label Biography information for Lord Harrison

385322

	registered interest
	date	24/06/2015
	answering body	Department for Business, Innovation and Skills
	answering dept id	26
	answering dept short name	Business, Innovation and Skills
	answering dept sort name	Business, Innovation and Skills
	hansard heading	Transatlantic Trade and Investment Partnership
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what progress has been made on the negotiations of the free trade agreement between the European Union and the United States.
	tabling member printed	The Earl of Shrewsbury
	uin	HL805
	answer	answer is ministerial correction date of answer 30/06/2015 answer text <p>Following the most recent round of negotiations for the EU-US Free Trade Agreement (FTA) which took place between 20 and 24 April in New York, there continues to be good progress on the technical work which would underpin the final deal. The next negotiating round is due to take place in July.</p><p> </p> answering member printed Lord Maude of Horsham question first answered 30/06/2015 12:09:28 answering member 115 label Biography information for Lord Maude of Horsham
	tabling member	2147 label Biography information for The Earl of Shrewsbury